106 related articles for article (PubMed ID: 12612963)
1. New strategies for the treatment of secondary hyperparathyroidism.
Akizawa T; Shiizaki K; Hatamura I; Kamimura M; Mizobuchi M; Narukawa N; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S100-3. PubMed ID: 12612963
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Management of secondary hyperparathyroidism of dialysis patients.
Akizawa T; Kamimura M; Mizobuchi M; Shiizaki K; Sumikado S; Sakaguchi T; Negi S; Ogata H; Kinugasa E
Nephrology (Carlton); 2003 Oct; 8 Suppl():S53-7. PubMed ID: 15012693
[TBL] [Abstract][Full Text] [Related]
4. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
5. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid glands in calcium regulation and human disease.
Akerström G; Hellman P; Hessman O; Segersten U; Westin G
Ann N Y Acad Sci; 2005 Apr; 1040():53-8. PubMed ID: 15891005
[TBL] [Abstract][Full Text] [Related]
7. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
8. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
Rodriguez M; Nemeth E; Martin D
Am J Physiol Renal Physiol; 2005 Feb; 288(2):F253-64. PubMed ID: 15507543
[TBL] [Abstract][Full Text] [Related]
9. [Basic and clinical aspects of calcimimetics. Effect of direct injection therapy in the expression of calcium-sensing receptor in parathyroid cell].
Shiizaki K; Tozawa R; Kusano E
Clin Calcium; 2008 Jan; 18(1):51-6. PubMed ID: 18175872
[TBL] [Abstract][Full Text] [Related]
10. Management of secondary hyperparathyroidism.
Cunningham J
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S35-40. PubMed ID: 16109140
[TBL] [Abstract][Full Text] [Related]
11. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
12. Advances in pharmacotherapy for secondary hyperparathyroidism.
Rodríguez M; Rodríguez-Ortiz ME
Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
[TBL] [Abstract][Full Text] [Related]
13. New therapies for uremic secondary hyperparathyroidism.
Torres PU; Prié D; Beck L; Friedlander G
J Ren Nutr; 2006 Apr; 16(2):87-99. PubMed ID: 16567265
[TBL] [Abstract][Full Text] [Related]
14. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
[TBL] [Abstract][Full Text] [Related]
15. Medical management of secondary hyperparathyroidism in chronic renal failure.
Goodman WG
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii2-8. PubMed ID: 12771290
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs for the treatment of secondary hyperparathyroidism.
Slatopolsky E; Brown AJ
Blood Purif; 2002; 20(1):109-12. PubMed ID: 11803167
[TBL] [Abstract][Full Text] [Related]
17. Different routes bridging calcium in Japanese hemodialysis patients.
Hamano T; Fujii N; Ito T; Imai E
Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
[TBL] [Abstract][Full Text] [Related]
18. [Renal failure and vitamin D].
Brown AJ; Dusso AS; Slatopolsky E
Clin Calcium; 2002 Jun; 12(6):711-23. PubMed ID: 15775356
[TBL] [Abstract][Full Text] [Related]
19. Bone disease in uremic patients: advances in PTH suppression.
Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
[TBL] [Abstract][Full Text] [Related]
20. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
